FDG PET-CT相关参数对鼻咽癌预后影响研究

目的 鼻咽癌是一种具有特殊地域性分布和生物学行为的头颈部肿瘤,研究显示FDG PET-CT相关参数在高发区鼻咽癌预后中具有一定价值。本研究探讨FDG PET-CT相关参数对低发区鼻咽癌的预后价值。方法 回顾分析2003—2013年在Albert Einstein医学院Beth Israel医疗中心诊治的 83例鼻咽癌患者资料,采用梯度法并依据PET-CT图像指导靶区勾画,获取FDG PET-CT参数 SUV_max、MTV、TLG。结果 3年样本数 37例,3年FFS率为74%,3年LRFS率为88%,3年DMFS率为85%。单因素分析结果显示 SUV_max、TLG是 3年LRFS和FFS的影响因素(P=0.004、0.014和 P=0.024、0.033),多因素分析结果显示 SUV_max是 3年FFS的影响因素。结论 治疗前原发肿瘤 SUV_max是影响鼻咽癌患者FFS的因素。

Prognostic values of 18 F-FDG PET/CT parameters in patients with nasopharyngeal carcinoma

Objective At present,nasopharyngeal carcinoma (NPC) is a head and neck cancer with special geographical distribution and biological behavior.Studies have shown that 18 F-FDG PET/CT parameters have certain prognostic values in patients with NPC in high-incidence areas.The aim of this study is to investigate the prognostic values of 18 F-FDG PET/CT parameters in patients with NPC in low-incidence areas.Methods The clinical data of 83 NPC patients who were diagnosed and treated in Beth Israel Medical Center, Albert Einstein Medical College from January 2003 to December 2013 were analyzed retrospectively.Based on 18 F-FDG PET/CT images,gross tumor volume (GTV) was delineated using the gradient method to obtain 18 F-FDG PET/CT parameters:maximum standardized uptake value (SUVmax ), metabolic tumor volume ( MTV),and total lesion glycolysis ( TLG).Results The number of patients followed was 37 at 3-years time.For all patients,the 3-year failure-free survival,locoregional relapse-free survival,and metastasis-free survival rates were 74%,88%,and 85%,respectively.The univariate analysis showed that SUVmax of the primary tumor (P=0.004) and TLG (P=0.014) were prognostic factors for 3-year locoregional relapse-free survival rate,and SUVmax of the primary tumor (P=0.024) and TLG (P=0.033) were prognostic factors for 3-year failure-free survival rate.The multivariate analysis showed that SUVmax of the primary tumor was the independent prognostic factor for 3-year failure-free survival rate. Conclusion SUVmax of the primary tumor before treatment is the independent prognostic factor for failure-free survival in patients with NPC.